Results 61 to 70 of about 1,721 (143)
Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat
Vericiguat is an oral soluble guanylate cyclase stimulator and enhances the cyclic guanosine monophosphate pathway independently of nitric oxide as well as synergistically in normal- and low-nitric oxide conditions.
Roessig, Lothar +7 more
core +1 more source
Clinical and Translational Science, Volume 19, Issue 2, February 2026.ABSTRACT Ecopipam, a selective dopamine D1 receptor antagonist in development for Tourette syndrome, is primarily converted by uridine diphosphate‐glucuronosyltransferase (UGT)1A9 to ecopipam glucuronide, with a minor metabolic pathway by cytochrome P450 3A4 forming EBS‐101‐40853 (also referred to as N‐desmethylecopipam or SCH 40853; also ...
Virginia D. Schmith +3 more
wiley +1 more source
Heat shock protein 90 mediates the protective effects of vericiguat on myocardial ischemia/reperfusion injury by inhibiting toll-like receptor 4 and c-Jun N-terminal kinases [PDF]
Iranian Journal of Basic Medical SciencesObjective(s): This study aimed to investigate whether vericiguat exerts a protective effect against myocardial ischemia-reperfusion injury (MIRI) by inhibiting toll-like receptor 4 (TLR4) and c-Jun N-terminal kinases (JNK) activation and whether heat ...
Sijie Pan +7 more
doaj +1 more source
Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines-Derived Medical Therapy [PDF]
Objective: To assess the efficacy of vericiguat compared to placebo in patients with decompensated heart failure, focusing on key outcomes such as hospitalisation rates, cardiovascular death, and side effects like gastrointestinal disturbances and ...
Waheed Ur Rehman +5 more
core +1 more source
, 2022 Background According to the new European Society of Cardiology (ESC) guidelines on the diagnostics and treatment of acute and chronic heart failure, vericiguat (Verquvo (R)) can be included in the treatment of adult patients with symptomatic chronic ...
Haase, Nadine +3 more
core +1 more source
European Journal of Clinical Investigation, Volume 56, Issue 2, February 2026.Vericiguat represents an optimal therapeutic option for older patients with heart failure with reduced ejection fraction (HFrEF). It possesses several advantages: once daily dosing, favourable tolerability, reassuring safety and limited drug–drug interactions.
Francesco Castelletti +7 more
wiley +1 more source
Experimental Physiology, Volume 111, Issue 2, Page 474-488, 1 February 2026.Abstract Heart failure (HF) with a mildly reduced ejection fraction (HFmrEF; 40%–49%) is present in ≤25% of HF patients. Therapeutic treatment options for HFmrEF‐associated exercise intolerance are limited. Nitric oxide (NO)‐independent stimulation of soluble guanylyl cyclase to improve peripheral vasodilatation offers a novel approach to enhance ...
Ramona E. Weber +10 more
wiley +1 more source
Cardiovascular Therapeutics, Volume 2026, Issue 1, 2026.Patients with hypertension, especially when complicated by cardiovascular disease (CVD) and/or comorbidities, require long‐term treatment with a combination of antihypertensive drugs, which often gives rise to complex drug regimens. Dual‐agent combination antihypertensive therapy is recommended in most patients with hypertension, and where available, a
Agostino Virdis, Irfan Ahmad
wiley +1 more source
Impact of Endothelial Diversity and Dysfunction on Cardiovascular Disease
Comprehensive Physiology, Volume 15, Issue 6, December 2025.The vascular endothelium is highly diverse, regulating permeability, vascular tone, repair, and inter‐organ communication. Endothelial heterogeneity supports tissue‐specific needs, but dysfunction drives cardiovascular disease. Transcriptomics, in vitro models, and redox signaling studies reveal therapeutic targets for precision treatment of ...
Anna E. Williams +6 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 6, Page 3826-3843, December 2025.This state‐of‐the‐art review outlines a practical, evidence‐based framework for early acute heart failure management to address critical gaps in current guidance and improve early treatment outcomes. Key components include early identification of co‐existing conditions, bedside haemodynamic profiling, a structured diagnostic approach incorporating both
Anika S. Naidu +22 more
wiley +1 more source